Literature DB >> 21569010

EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells.

An De Weer1, Joni Van der Meulen, Pieter Rondou, Tom Taghon, Torsten A Konrad, Katleen De Preter, Pieter Mestdagh, Tom Van Maerken, Nadine Van Roy, Marta Jeison, Isaac Yaniv, Barbara Cauwelier, Lucien Noens, Hélène-Antoine Poirel, Peter Vandenberghe, Frédéric Lambert, Anne De Paepe, Maria García Sánchez, Maria Odero, Bruno Verhasselt, Jan Philippé, Joke Vandesompele, Rotraud Wieser, Nicole Dastugue, Pieter Van Vlierberghe, Bruce Poppe, Frank Speleman.   

Abstract

Chromosomal rearrangements involving the MECOM (MDS1 and EVI1 complex) locus are recurrent genetic events in myeloid leukaemia and are associated with poor prognosis. In this study, we assessed the role of MECOM locus protein EVI1 in the transcriptional regulation of microRNAs (miRNAs) involved in the leukaemic phenotype. For this, we profiled expression of 366 miRNAs in 38 MECOM-rearranged patient samples, normal bone marrow controls and MECOM (EVI1) knock down/re-expression models. Cross-comparison of these miRNA expression profiling data showed that MECOM rearranged leukaemias are characterized by down regulation of MIR449A. Reconstitution of MIR449A expression in MECOM-rearranged cell line models induced apoptosis resulting in a strong decrease in cell viability. These effects might be mediated in part by MIR449A regulation of NOTCH1 and BCL2, which are shown here to be bona fide MIR449A targets. Finally, we confirmed that MIR449A repression is mediated through direct promoter occupation of the EVI1 transcriptional repressor. In conclusion, this study reveals MIR449A as a crucial direct target of the MECOM locus protein EVI1 involved in the pathogenesis of MECOM-rearranged leukaemias and unravels NOTCH1 and BCL2 as important novel targets of MIR449A. This EVI1-MIR449A-NOTCH1/BCL2 regulatory axis might open new possibilities for the development of therapeutic strategies in this poor prognostic leukaemia subgroup.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569010     DOI: 10.1111/j.1365-2141.2011.08737.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Notch signal integration in the vasculature during remodeling.

Authors:  Bahman Rostama; Sarah M Peterson; Calvin P H Vary; Lucy Liaw
Journal:  Vascul Pharmacol       Date:  2014-11       Impact factor: 5.773

2.  EVI1 splice variants modulate functional responses in ovarian cancer cells.

Authors:  Punashi Dutta; Tuyen Bui; Kyle A Bauckman; Khandan Keyomarsi; Gordon B Mills; Meera Nanjundan
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

3.  Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.

Authors:  Carolyn Glass; Charles Wuertzer; Xiaohui Cui; Yingtao Bi; Ramana Davuluri; Ying-Yi Xiao; Michael Wilson; Kristina Owens; Yi Zhang; Archibald Perkins
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

4.  EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Authors:  Gerwin Heller; Anna Rommer; Katarina Steinleitner; Julia Etzler; Hubert Hackl; Petra Heffeter; Erwin Tomasich; Martin Filipits; Birgit Steinmetz; Thais Topakian; Simone Klingenbrunner; Barbara Ziegler; Andreas Spittler; Sabine Zöchbauer-Müller; Walter Berger; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2015-03-21       Impact factor: 17.388

5.  Investigating the inhibitory effect of miR-34a, miR-449a, miR-1827, and miR-106b on target genes including NOTCH1, c-Myc, and CCND1 in human T cell acute lymphoblastic leukemia clinical samples and cell line.

Authors:  Tohid Naderi; Samira Mohammadi-Yeganeh; Neda Mohammadi-Hezaveh; Razie Hadavi; Ahmad Gharehbaghian; Nader Vazifeh-Shiran; Vahid Fallah Azad; Mahdi Paryan
Journal:  Iran J Basic Med Sci       Date:  2020-03       Impact factor: 2.699

Review 6.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037

7.  MicroRNA expression profiling of endocrine sensitive and resistant breast cancer cell lines.

Authors:  Maitham A Khajah; Alyaa Al-Ateyah; Yunus A Luqmani
Journal:  Biochem Biophys Rep       Date:  2022-07-20

8.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.

Authors:  Birgit Steinmetz; Hubert Hackl; Eva Slabáková; Ilse Schwarzinger; Monika Smějová; Andreas Spittler; Itziar Arbesu; Medhat Shehata; Karel Souček; Rotraud Wieser
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Role of miR-96/EVI1/miR-449a Axis in the Nasopharyngeal Carcinoma Cell Migration and Tumor Sphere Formation.

Authors:  Lai-Sheung Chan; Hong-Lok Lung; Roger Kai-Cheong Ngan; Anne Wing-Mui Lee; Sai Wah Tsao; Kwok-Wai Lo; Michael Kahn; Maria Li Lung; Rotraud Wieser; Nai-Ki Mak
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.